Anteris Technologies Global Corp. The company is headquartered in Toowong, Australia.
| Revenue (TTM) | $1.85M |
| Gross Profit (TTM) | $1.38M |
| EBITDA | $-94.43M |
| Operating Margin | -4860.00% |
| Return on Equity | -59.20% |
| Return on Assets | -34.00% |
| Revenue/Share (TTM) | $0.04 |
| Book Value | $2.86 |
| Price-to-Book | 3.58 |
| Price-to-Sales (TTM) | 521.68 |
| EV/Revenue | 387.54 |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -11.20% |
| Shares Outstanding | $97.34M |
| Float | $60.31M |
| % Insiders | 16.47% |
| % Institutions | 66.19% |
Volatility is currently contracting
MINNEAPOLIS and BRISBANE, Australia, May 13, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, announced the appointment of Ms. Susan Knight and Mr.
MINNEAPOLIS and BRISBANE, Australia, May 05, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR), a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced that the first patients in the United States have been enrolled and successfully treated in the DurAVR® Transcatheter Heart Valve (“THV”) global pivotal trial for patients with severe calcific aortic stenosis (the “PARADIGM Trial”). The procedures were performed by Azeem Latib, M.D.
MINNEAPOLIS and BRISBANE, Australia, April 28, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR), a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced it has secured U.S. Medicare reimbursement eligibility for the global pivotal PARADIGM Trial under a Centers for Medicare & Medicaid Services (CMS) national coverage policy. Eligible procedures performed at participating U.S. study sites are covered under the Transcatheter Aortic Valve Replacement (TAVR) National Coverage Determination 20.32.
Anteris Technologies is developing DurAVR, a differentiated biomimetic TAVR device with encouraging early clinical data in over 130 patients. AVR's PARADIGM pivotal trial is the central catalyst. This will compare DurAVR against commercial valves across 85 sites in the US, Europe, and Canada. I believe that Medtronic's 16.2% stake also offers strategic validation of AVR's underlying valve technology.
